Individualized pharmacotherapy with paclitaxel

Current Opinion in Oncology

Volumn 19, Issue 6, 2007, Pages 586-589

  Mielke, Stephan ^a,b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

CYP450; Organic anion transporting polypeptide; P glycoprotein; Paclitaxel; Pharmacogenetic; Pharmacokinetic

Indexed keywords

BILIRUBIN; CYTOCHROME P450; GLYCOPROTEIN P; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1B3 PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

AGE; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG TRANSPORT; ENZYME METABOLISM; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; NEUROTOXICITY; NEUTROPENIA; OCCUPATIONAL EXPOSURE; PATIENT SAFETY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

AGE FACTORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BILIRUBIN; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; P-GLYCOPROTEIN; PACLITAXEL; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 34848842452     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282a08f8c     Document Type: Review

References (31)

1. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-1014.
2. Sparreboom A, Figg WD. Identifying sources of interindividual pharmacokinetic variability with population modeling. Clin Cancer Res 2006; 12:1951-1953.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
4. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-1268.
5. Kim TY, Kim DW, Chung JY, et al. Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res 2004; 10:3708-3716.
6. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038-1044.
7. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-2666.
8. Sparreboom A, Van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996; 56:2112-2115.
9. Gelderblom H, Mross K, Ten Tije AJ, et al. Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-h infusions. J Clin Oncol 2002; 20:574-581.
10. Mielke S, Sparreboom A, Steinberg SM, et al. Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 2005; 11:4843-4850.
11. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13:180-190.
12. Mielke S, Sparreboom A, Behringer D, Mross K. Paclitaxel pharmacokinetics and response to chemotherapy in patients with advanced cancer treated with a weekly regimen. Anticancer Res 2005; 25:4423-4427.
13. Huizing MT, Giaccone G, Van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with nonsmall-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997; 15:317-329.
14. Sparreboom A, Verweij J. Paclitaxel pharmacokinetics, threshold models, and dosing strategies. J Clin Oncol 2003; 21:2803-2804.
15. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer 2006; 42:24-30.
16. Mielke S, Mross K, Gerds TA, et al. Comparative neurotoxicity of weekly nonbreak paclitaxel infusions over 1 versus 3 h. Anticancer Drugs 2003; 14:785-792.
17. Henningsson A, Karlsson MO, Vigano L, et al. Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol 2001; 19:4065-4073.
18. Smorenburg CH, Sparreboom A, Bontenbal M, et al. Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel. J Clin Oncol 2003; 21:197-202.
19. Miller AA, Rosner GL, Egorin MJ, et al. Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763. Clin Cancer Res 2004; 10:8325-8331.
20. Mross K, Hollander N, Unger C, Massing U. Flat dose (175 mg/weekly) paclitaxel: pharmacokinetics and clinical implications. Int J Clin Pharmacol Ther 2005; 43:601-602.
21. Joerger M, Huitema AD, Van den Bongard DH, et al. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors. Clin Cancer Res 2006; 12:2150-2157. Retrospective, very comprehensive population pharmacokinetic modeling analysis on 168 patients treated with paclitaxel. Gender, BSA, age and serum bilirubin levels were correlated with the disposition and elimination pathways of paclitaxel.
22. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res 2006; 4:135-150.
23. Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275:566-575.
24. Henningsson A, Marsh S, Loos WJ, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11:8097-8104.
25. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 2006; 80:179-191. These authors succeeded in discovering the relationship between paclitaxel pharmacokinetics and a particular genotype encoding the cytochrome P450 protein. In this study population of 235 Japanese patients a CYP3A4 haplotype was associated with a reduced 3′-p-hydroxylation of paclitaxel and reduced levels of the metabolite 6α-hydroxypaclitaxel.
26. Sissung TM, Mross K, Steinberg SM, et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 2006; 42:2893-2896. Particular ABCB1 genotypes encoding P-glycoprotein (MDR1) were associated with the development of neutropenia and cumulative peripheral neuropathy in cancer patients treated with a weekly regimen of paclitaxel. These side effects were independent of the underlying pharmacokinetics, suggesting that they might have been linked to inherited variants of ABCB1 through a distinct mechanism.
27. Smith NF, Acharya MR, Desai N, et al. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 2005; 4:815-818.
28. Smith NF, Marsh S, Scott-Horton TJ, et al. Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther 2007; 81:76-82. This retrospective study investigated the effect of three known, nonsynonymous single nucleotide polymorphisms in SLCO1B3 in white cancer patients.
29. Fruscio R, Lissoni AA, Frapolli R, et al. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemother Pharmacol 2006; 58:319-325.
30. Woo MH, Relling MV, Sonnichsen DS, et al. Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias. Clin Cancer Res 1999; 5:543-549.
31. De Jonge ME, Van den Bongard HJ, Huitema AD, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with nonsmall cell lung cancer. Clin Cancer Res 2004; 10:2237-2244.